Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 March, 2018 00:04 IST
Panacea Biotec receives EIR for oncology manufacturing facility
Source: IRIS | 12 Mar, 2018, 10.40AM
Comments  |  Post Comment

Panacea Biotec announced the receipt of Establishment Inspection Report (EIR) from the U.S. Food & Drug Administration ('USFDA') indicating the formal closure of the Inspection conducted by USFDA, at its Pharmaceutical Formulation Facility for Oncology Parenteral and Oral Solids Dosage at Malpur, Baddi, District Solan, Himachal Pradesh, India.

Shares of the company gained Rs 9.7, or 3.45%, to trade at  Rs 290.75.  The total volume of shares traded  was  12,527 at the BSE (10.29 a.m., Monday).

Panacea Biotec Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Ashok Leyland bags orders for 2,100 buses from Tamil Nadu - 21-Mar-2018 10:17
Suzlon designs and produces India's longest wind turbine blade - 21-Mar-2018 10:11
Mphasis partners with Plug and Play - 21-Mar-2018 09:55
Force Motors signs JV agreement with MTU Friedrichshafen GmbH - 21-Mar-2018 09:48
TCS partners with Saudi Real Estate Refinance Co - 21-Mar-2018 09:44
GE Power India secures contract worth Rs 3.09 bn - 21-Mar-2018 09:40
Alembic Pharm intimates of USFDA inspection of facility at Panelav - 21-Mar-2018 09:37
Mahindra & Mahindra partners with Standard Chartered - 20-Mar-2018 12:36
BHEL commissions 1st unit of Kishanganga hydro-electric project - 20-Mar-2018 10:12
Suzlon wins two projects of 300 MW and 200 MW each under SECI bid - 20-Mar-2018 10:08
Granules India receives approval for Metformin ER tablets - 20-Mar-2018 10:05
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer